Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P447

Early initiation of adalimumab significantly diminishes post-operative Crohn's Disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial

Authors:

E. Scapa*1, N. Maharshak2, Y. Kariv3, S. Ben-Horin4, I. White5, E. Santo6, H. Tulchinsky7, I. Dotan2

1Tel-Aviv Sourasky Medical Center, Gastroenterology, Tel-Aviv, Israel, 2Tel Aviv Medical Center, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, 3Tel Aviv Sourasky Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Proctology Unit, Department of Surgery, Tel Aviv, Israel, 4Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 5Meir Medical Center, Surgery, Kfar Saba, Israel, 6Tel Aviv Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, Tel Aviv, Israel, 7Tel Aviv Medical Center affiliated to Sackler Faculty of Medicine, Tel Aviv university, Surgery, Tel Aviv, Israel

P448.

Inflammatory and cancerous skin lesions in inflammatory bowel disease patients treated with anti-TNF therapy

Authors:

A. Ocepek, C. Pernat Drobez, UMC Maribor, Gastroenterology, Maribor, Slovenia

P448. Long-term remission among Crohn's disease patients on immunosuppressive therapy after infliximab withdrawal: a retrospective, monocentric study comparing induction alone to a 1-year maintenance therapy
Authors:

A. Chauvin1, A. Amiot1, A. Le Thuault2, Y. Le Baleur1, M. Belhassan1, S. Bastuji Garin2, J.C. Delchier1, 1Henri Mondor Hospital, Paris Est Creteil University, Gastroenterology, Creteil, France, 2Henri Mondor Hospital, Paris Est Creteil University, Public Health, Creteil, France

P448. Polymorphisms in IL‑33, IL1RL1 genes and risk of inflammatory bowel disease
P448

How good are we at detecting and managing folate deficiency in inflammatory bowel disease?

Authors:

S. Subramaniam*1, K. Besherdas2

1University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom, 2Barnet & Chase Farm Hospitals, Royal Free London NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom

P449.

Inflammatory bowel disease patients' partner – how important is their support?

Authors:

A. Lahat, S. Neuman, R. Eliakim, S. Ben-Horin, Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel

P449. Different genetic expression profiles of oxidative stress and apoptosis related genes in active and inactive Crohn's disease
P449. Long-term increase of serum cholesterol level in ulcerative colitis patients treated with cyclosporine: an underdiagnosed side effect frequently associated with other drug-related complications
Authors:

A. Balint1, K. Farkas1, S. Monika2, Z. Szepes1, F. Nagy1, T. Wittmann1, T. Molnar1, 1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary

P449

Anti-drug Antibodies Inhibit Neutralization of TNF-alpha in Infliximab Treated Patients with Inflammatory Bowel Disease (IBD)

Authors:

A. Eser*1, H. Vogelsang1, S. Reinisch2, G. Novacek1, C. Dejaco1, L. Kazemi-Shirazi1, C. Primas1, C. Lichtenberger1, S. Brehovsky1, S. Singh3, A. Jain3, W. Reinisch2

1Medical University of Vienna, Dept. for Gastroenterology and Hepatology, Vienna, Austria, 2McMaster University, Department of Internal Medicine, Hamilton, Canada, 3Prometheus Laboratories, Department of Research and Development, San Diego, United States

P450.

Inflammatory bowel disease patients' satisfaction with hospital care – a novel evaluation model

Authors:

B. Moreira Gonçalves1, A. Sofia Marinho1, F. Dália1, A. Célia Caetano1, S. Costa1, F. Magro2, R. Gonçalves1, J.B. Soares1, 1Hospital Braga, Gastroenterology Department, Braga, Portugal, 2Centro Hospitalar São João, Gastroenterology Department, Porto, Portugal

P450. Long-term impacts of colectomy surgery among ulcerative colitis patients study (LOCUS): the final analysis
Authors:

C. Brown1, P. Gibson2, A. Hart3, G. Kaplan4, E. Hautamaki5, E. Flood5, T. Fan6, L. Stokes6, K. Beusterien5, 1St. Paul's Hospital, Division of General Surgery, Vancouver, Canada, 2The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia, 3St. Mark's Hospital NWLH NHS Trust, Department of Medicine, London, United Kingdom, 4University of Calgary, Departments of Medicine and Community Health Sciences, Calgary, Canada, 5Oxford Outcomes Inc., Bethesda, United States, 6Merck & Co., Whitehouse Station, United States

P450. The impact of PPARγ genetic variants on IBD susceptibility and IBD disease course [Swiss IBD Cohort Study Group1]
P450

Poor recognition and management of iron deficiency anaemia in inflammatory bowel disease: a missed opportunity

Authors:

S. Subramaniam*1, K. Besherdas2

1University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom, 2Barnet & Chase Farm Hospitals, Royal Free London NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom

P451.

Induction of remission in Crohn's disease in children and young adults using a Crohn's Disease Exclusion Diet (CDED)

Authors:

A. Levine, R. Sigal, T. Pfeffer Gik, Wolfson Medical Center, Pediatric Gastroenterology Unit, Holon, Israel

P451. Long-term follow-up in patients with ulcerative colitis treated with tacrolimus: early and long-term data from a retrospective observational study
Authors:

M. Matsuura1, H. Nakase1, T. Yoshino1, T. Chiba1, 1Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan

P451. Phenotype–genotype profile in Crohn's disease predicted by genetic markers in autophagy-related genes
P451

Cost of hospitalisations among moderate-to-severe Ulcerative Colitis patients treated with adalimumab and conventional non-biologic therapies

Authors:

S. Wang*1, H. Yang2, E. Faust2, Y. Bao1

1AbbVie Inc., Global Health Economics and Outcomes Research, North Chicago, IL, United States, 2Analysis Group, Inc., Boston, MA, United States

P452.

Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program

Authors:

M. Daperno1,2, M. Comberlato3,4, F. Bossa4,5, A.G. Bonanomi4,6, G. Lombardi4,7, L. Biancone4,8, R. Cosintino4,9, R. D'Incà4,10, A. Cassinotti4,11, R. Mangiarotti4,9, A. Papa4,12, R. Pica4,13, F. Rizzello4,14, A. Armuzzi4,12, A. Orlando4,15, on behalf of IG-IBD4, 1Fondazione IBD Onlus, IBD Foundation, Torino, Italy, 2AO Ordine Mauriziano, Gastroenterology Division, Turin, Italy, 3Ospedale di Bolzano, Gastroenterology, Bolzano, Italy, 4IGIBD, Italian Group for IBD, Florence, Italy, 5Casa del Sollievo Divina Provvidenza, Gastroenterology, San Giovanni Rotondo, Italy, 6A.O. Careggi, Gastroenterology Division, Florence, Italy, 7AORN A. Cardarelli, Napoli, UOC of Gastroenterology, Napoli, Italy, 8Tor Vergata University, Internal Medicine, Rome, Italy, 9A.O.San Camillo Forlanini, Gastroenterology Unit, Rome, Italy, 10University of Padova, Gastroenterology Department, Padova, Italy, 11Luigi Sacco University Hospital, Gastroenterology Department, Milano, Italy, 12Catholic University, Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Rome, Italy, 13Pertini Hospital, Gastroenterology Unit, Roma, Italy, 14S. Orsola Malpighi Hospital, Internal Medicine, Bologna, Italy, 15AO Villa Sofia-Cervello, Internal Medicine, Palermo, Italy

P452. Hypermethylation status in relation to chronic inflammation of inflammatory bowel disease
P452. Long-term efficacy and safety of cyclosporine as a rescue therapy in acute, steroid-refractory severe ulcerative colitis
Authors:

A. Balint1, K. Farkas1, Z. Szepes1, F. Nagy1, S. Monika2, T. Wittmann1, T. Molnar1, 1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary